The vaccine, announced earlier this week by Russia’s sovereign wealth fund, claims an “interim efficacy” of 91.4%, from its ongoing phase-3 trials
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.